For targets of mutual interest, we combine our capabilities in early discovery with our partners’ capability in clinical development to accelerate project implementation, ensuring that patients have access to effective and safe medications as soon as possible.

We license or assign our promising PCC products to our partners for subsequent development.

To bring our innovative “first-in-class” (FIC) /“best-in-class” (BIC) PCC products into clinical, we collaborate with our partners to establish disease area focused joint venture, products.